{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T22:08:13Z","timestamp":1788905293191,"version":"build-2803163510"},"reference-count":40,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019854","name":"Greater Copenhagen Health Science Partners","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["1030-00232B"],"award-info":[{"award-number":["1030-00232B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jidinnovations.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JID Innovations"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xjidi.2026.100525","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T23:33:59Z","timestamp":1786577639000},"page":"100525","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An immunocompetent transplantable mouse model of basal cell carcinoma"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6999-0557","authenticated-orcid":false,"given":"Martin","family":"Wiinberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9994-7848","authenticated-orcid":false,"given":"Kristian K.","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3653-6424","authenticated-orcid":false,"given":"Catharina M.","family":"Lerche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1048-127X","authenticated-orcid":false,"given":"Thomas L.","family":"Andresen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6068-901X","authenticated-orcid":false,"given":"Thomas","family":"Litman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-2035","authenticated-orcid":false,"given":"Merete","family":"Haedersdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4578-684X","authenticated-orcid":false,"given":"Uffe H.","family":"Olesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xjidi.2026.100525_bib1","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1038\/nm1622","article-title":"Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy","volume":"13","author":"Apetoh","year":"2007","journal-title":"Nat Med"},{"key":"10.1016\/j.xjidi.2026.100525_bib2","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrd4090","article-title":"Phase II and Phase III attrition rates 2011\u20132012","volume":"12","author":"Arrowsmith","year":"2013","journal-title":"Nat. Rev. Drug Discov"},{"key":"10.1016\/j.xjidi.2026.100525_bib3","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2026.100525_bib4","first-page":"2145","article-title":"Intradermal Injection, as Opposed to Subcutaneous Injection, Enhances Immunogenicity and Suppresses Tumorigenicity of Tumor Cells 1","volume":"63","author":"Bonnotte","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.xjidi.2026.100525_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1320614","article-title":"Dissecting tumor microenvironment heterogeneity in syngeneic mouse models: insights on cancer-associated fibroblast phenotypes shaped by infiltrating T cells","volume":"14","author":"Carretta","year":"2024","journal-title":"Front. Immunol"},{"key":"10.1016\/j.xjidi.2026.100525_bib6","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/s41590-022-01267-2","article-title":"The complex role of tumor-infiltrating macrophages","volume":"23","author":"Christofides","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.xjidi.2026.100525_bib7","doi-asserted-by":"crossref","DOI":"10.1177\/17588359211066147","article-title":"Brief overview: cemiplimab for the treatment of advanced basal cell carcinoma: PD-1 strikes again","volume":"14","author":"Davis","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.xjidi.2026.100525_bib8","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat. Rev. Immunol"},{"key":"10.1016\/j.xjidi.2026.100525_bib9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrc.2017.92","article-title":"Preclinical mouse solid tumour models: status quo, challenges and perspectives","volume":"17","author":"Gengenbacher","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.xjidi.2026.100525_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/73417","article-title":"Basal cell carcinomas in mice overexpressing Gli2 in skin","volume":"24","author":"Grachtchouk","year":"2000","journal-title":"Nat. Genet"},{"key":"10.1016\/j.xjidi.2026.100525_bib11","doi-asserted-by":"crossref","first-page":"28341","DOI":"10.1074\/jbc.C000352200","article-title":"Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma","volume":"275","author":"Hahn","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.xjidi.2026.100525_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0055146","article-title":"Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer","volume":"8","author":"Ino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2026.100525_bib13","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1600-0560.1999.tb01814.x","article-title":"Cytokeratin 15 expression in trichoepitheliomas and a subset of basal cell carcinomas suggests they originate from hair follicle stem cells","volume":"26","author":"Jih","year":"1999","journal-title":"J. Cutan. Pathol. Blackwell Munksgaard"},{"key":"10.1016\/j.xjidi.2026.100525_bib14","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1038\/s41598-022-07153-z","article-title":"Different syngeneic tumors show distinctive intrinsic tumor-immunity and mechanisms of actions (MOA) of anti-PD-1 treatment","volume":"12","author":"Jin","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.xjidi.2026.100525_bib15","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","article-title":"Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials","volume":"84","author":"Johnson","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.xjidi.2026.100525_bib16","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/eji.201545797","article-title":"The site of tumor development determines immunogenicity via temporal mobilization of antigen-laden dendritic cells in draining lymph nodes","volume":"46","author":"Joncker","year":"2016","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.xjidi.2026.100525_bib17","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/00000372-200112000-00001","article-title":"Cytokeratins as Markers of Follicular Differentiation","volume":"23","author":"Kurzen","year":"2001","journal-title":"Am. J. Dermatopathol"},{"key":"10.1016\/j.xjidi.2026.100525_bib18","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1158\/1078-0432.CCR-17-3726","article-title":"Clinical Relevance and Suppressive Capacity of Human Myeloid-Derived Suppressor Cell Subsets","volume":"24","author":"Lang","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xjidi.2026.100525_bib19","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1083\/jcb.129.5.1329","article-title":"The basal keratin network of stratified squamous epithelia: defining K15 function in the absence of K14","volume":"129","author":"Lloyd","year":"1995","journal-title":"J. Cell Biol"},{"key":"10.1016\/j.xjidi.2026.100525_bib20","first-page":"447","article-title":"Parsing clinical success rates","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.xjidi.2026.100525_bib21","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1078-0432.CCR-18-1122","article-title":"Keratinocyte carcinomas: Current concepts and future research priorities","volume":"25","author":"Nagarajan","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.xjidi.2026.100525_bib22","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.jaad.2022.06.1206","article-title":"Immunotherapy for keratinocyte cancers. Part I: Immune-related epidemiology, risk factors, pathogenesis, and immunotherapy management of keratinocyte cancers","volume":"88","author":"Neuner","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.xjidi.2026.100525_bib23","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1073\/pnas.97.7.3438","article-title":"Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1","volume":"97","author":"Nilsson","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.xjidi.2026.100525_bib24","first-page":"4490","article-title":"Synergy between Chemotherapy and Immunotherapy in the Treatment of Established Murine Solid Tumors 1","volume":"63","author":"Nowak","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.xjidi.2026.100525_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115561","article-title":"Epigenomic regulation of stemness contributes to the low immunogenicity of the most mutated human cancer","volume":"44","author":"Oka","year":"2025","journal-title":"Cell Rep"},{"key":"10.1016\/j.xjidi.2026.100525_bib26","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.3390\/cancers13246326","article-title":"Anti-pd-1 therapy with adjuvant ablative fractional laser improves anti-tumor response in basal cell carcinomas","volume":"13","author":"Olesen","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xjidi.2026.100525_bib27","doi-asserted-by":"crossref","first-page":"5815","DOI":"10.3390\/cancers14235815","article-title":"Feasibility of Intratumoral Anti-PD1 as Treatment of Human Basal Cell Carcinoma: An Explorative Study with Adjuvant Ablative Fractional Laser","volume":"14","author":"Omland","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xjidi.2026.100525_bib28","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1126\/science.276.5313.817","article-title":"Basal Cell Carcinomas in Mice Overexpressing Sonic Hedgehog","volume":"276","author":"Oro","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.xjidi.2026.100525_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113254","article-title":"European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma\u2014update 2023","volume":"192","author":"Peris","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.xjidi.2026.100525_bib30","doi-asserted-by":"crossref","first-page":"628","DOI":"10.3390\/diagnostics11040628","article-title":"ARG1 mRNA Level Is a Promising Prognostic Marker in Head and Neck Squamous Cell Carcinomas","volume":"11","author":"Pokr\u00fdvkov\u00e1","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.xjidi.2026.100525_bib31","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1038\/labinvest.3780180","article-title":"K15 Expression Implies Lateral Differentiation within Stratified Epithelial Basal Cells","volume":"80","author":"Porter","year":"2000","journal-title":"Lab Invest"},{"key":"10.1016\/j.xjidi.2026.100525_bib33","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41389-022-00398-3","article-title":"Neutrophils and polymorphonuclear myeloid-derived suppressor cells: an emerging battleground in cancer therapy","volume":"11","author":"Raskov","year":"2022","journal-title":"Oncogenesis"},{"key":"10.1016\/j.xjidi.2026.100525_bib34","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1186\/s12885-021-08974-3","article-title":"Tumor-immune profiling of CT-26 and Colon 26 syngeneic mouse models reveals mechanism of anti-PD-1 response","volume":"21","author":"Sato","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.xjidi.2026.100525_bib35","first-page":"275","article-title":"False discovery rates: A new deal","volume":"18","author":"Stephens","year":"2017","journal-title":"Biostatistics"},{"key":"10.1016\/j.xjidi.2026.100525_bib36","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/S1470-2045(21)00126-1","article-title":"Cemiplimab in locally advanced basal cell carcinoma after hedgehog inhibitor therapy: an open-label, multi-centre, single-arm, phase 2 trial","volume":"22","author":"Stratigos","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.xjidi.2026.100525_bib37","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1038\/jid.2011.204","article-title":"Establishment of murine basal cell carcinoma allografts: A potential model for preclinical drug testing and for molecular analysis","volume":"131","author":"Wang","year":"2011","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.xjidi.2026.100525_bib38","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccr.2010.11.007","article-title":"Basal cell carcinomas arise from hair follicle stem cells in Ptch1+\/- mice","volume":"19","author":"Wang","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xjidi.2026.100525_bib39","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/34201","article-title":"Activating Smoothened mutations in sporadic basal-cell carcinoma","volume":"391","author":"Xie","year":"1998","journal-title":"Nature"},{"key":"10.1016\/j.xjidi.2026.100525_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0206223","article-title":"Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments","volume":"13","author":"Yu","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.xjidi.2026.100525_bib41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nri2216","article-title":"Immunological aspects of cancer chemotherapy","volume":"8","author":"Zitvogel","year":"2008","journal-title":"Nat Rev Immunol"}],"container-title":["JID Innovations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2667026726000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T21:23:23Z","timestamp":1788902603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2667026726000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2667026726000792"],"URL":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100525","relation":{},"ISSN":["2667-0267"],"issn-type":[{"value":"2667-0267","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An immunocompetent transplantable mouse model of basal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"JID Innovations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xjidi.2026.100525","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}],"article-number":"100525"}}